Product Description
mRNA Covid-19 Vaccine
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Jiangsu Rec-Biotechnology Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: COVID-19
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05351450 |
R520A101 | P1 |
Not yet recruiting |
COVID-19 |
2023-02-01 |
2022-04-29 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|